|PR Newswire Association LLC|
Get the most recent insight from
Here are highlights from Wednesday's Analyst Blog:
Patent Relief for Pfizer
The reissue patent will provide coverage up to
Pfizer, which is facing patent challenges from several companies for Celebrex, immediately put into action plans to delay the entry of generic competition. The company has filed patent infringement lawsuits against generic players –
All these companies are seeking
We are positive on the granting of the reissue patent which buys time for Pfizer to generate additional sales from Celebrex before generics enter the market. With Lipitor losing exclusivity, Celebrex was among the top contributors to US sales in 2012. Celebrex sales increased 8% to
Pfizer currently carries a Zacks Rank #3 (Hold). While near-term earnings will be driven by cost cutting efforts and share repurchases, longer-term growth will depend on the success of drug development. The company's pipeline needs to deliver given the Lipitor loss of exclusivity and the upcoming loss of exclusivity on additional products in the next few years.
ProAssurance Raised to Outperform
Why the Upgrade?
Despite a soft cycle in the medical liability business,
Prudent capital management is another key strength for
Further, the company deploys capital in an effective manner mainly through its stock buyback program and dividend payment. The company deployed
Want more from
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from
Zacks.com is a property of
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.